Acetyl-11-Keto-β-Boswellic Acid (AKBA) is an active triterpenoid compound from the extract of Boswellia serrate; a novel Nrf2 activator.IC50 value:Target: Nrf2 activatorin vitro: AKBA significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in brain tissues in middle cerebral artery occlusion (MCAO) rats at 48 hours post reperfusion. In primary cultured neurons, AKBA increased the Nrf2 and HO-1 expression, w
3-Acetyl-11-keto-beta-boswellic acid is a triterpenoid.
View more+(3R,4R,6aR,6bS,8aR,11R,12S,12aR,14bS)-3-(acetyloxy)-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid (3R,4R,6aR,6bS,8aR,11R,12S,12aR,14bS)-3-(acetyloxy)-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid (3α)-3-(acetyloxy)-11-oxours-12-en-24-oic acid (3α)-3-Acetoxy-11-oxours-12-en-24-oic acid (3α,5ξ,9ξ)-3-Acetoxy-11-oxours-12-en-24-oic acid 3-ACETYL-11-KETONE-BETA-ACETYLBOSWELLIC ACID 3-Acetyl-11-keto-Β-boswellic Acid 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID 3-O-Acetyl-11-keto-Β-boswellic acid 3α-Acetoxy-11-keto-β-boswellic acid ACETYL-11-KETO-B-BOSWELLIC ACID, 3 ACETYL-11-KETO-BETA-BOSWELLIC ACID AKBA AK-BETABA BOSWELLIC ACID, ACETYL KETO Urs-12-en-24-oic acid, 3-(acetyloxy)-11-oxo-, (3α)- Urs-12-en-24-oic acid, 3-(acetyloxy)-11-oxo-, (3α,5ξ,9ξ)-
The Acetyl-11-keto-beta-boswellic acid is an organic compound with the formula C32H48O5. The systematic name of this chemical is (3α)-3-(acetyloxy)-11-oxours-12-en-24-oic acid. With the CAS registry number 67416-61-9, it is also named as urs-12-en-24-oic acid, 3-(acetyloxy)-11-oxo-, (3α)-. The product's categories are Miscellaneous Natural Products; Pharmaceuticals. Besides, it should be stored at temperature of -20 °C.
Physical properties about Acetyl-11-keto-beta-boswellic acid are: (1)ACD/LogP: 8.00; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 6.76; (4)ACD/LogD (pH 7.4): 4.97; (5)ACD/BCF (pH 5.5): 40485.62; (6)ACD/BCF (pH 7.4): 663.88; (7)ACD/KOC (pH 5.5): 30680.92; (8)ACD/KOC (pH 7.4): 503.11; (9)#H bond acceptors: 5; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 3; (12)Polar Surface Area: 69.67 Å2; (13)Index of Refraction: 1.549; (14)Molar Refractivity: 143.22 cm3; (15)Molar Volume: 450.1 cm3; (16)Polarizability: 56.77×10-24cm3; (17)Surface Tension: 45.7 dyne/cm; (18)Density: 1.13 g/cm3; (19)Flash Point: 184.4 °C; (20)Enthalpy of Vaporization: 97.58 kJ/mol; (21)Boiling Point: 600.3 °C at 760 mmHg; (22)Vapour Pressure: 5.85E-16 mmHg at 25°C.
When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)[C@@]1(C)[C@H](OC(=O)C)CC[C@@]3(C)[C@H]1CC[C@]2([C@]5(/C(=C\C(=O)[C@@H]23)[C@@H]4[C@H]([C@@H](CC[C@]4(C)CC5)C)C)C)C
(2)InChI: InChI=1/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
(3)InChIKey: HMMGKOVEOFBCAU-BCDBGHSCBM
(4)Std. InChI: InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
(5)Std. InChIKey: HMMGKOVEOFBCAU-BCDBGHSCSA-N
no data available
Pictogram(s) | no data available |
---|---|
Signal word | no data available |
Hazard statement(s) | no data available |
Precautionary statement(s) | |
Prevention | no data available |
Response | no data available |
Storage | no data available |
Disposal | no data available |
no data available
AKBA (Acetyl-11-keto-β-boswellic acid) significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in brain tissues in middle cerebral artery occlusion (MCAO) rats at 48 hours post reperfusion. In primary cultured neurons, AKBA increased the Nrf2 and HO-1 expression, which provided protection against OGD-induced oxidative insult. Additionally, AKBA treatment increased Nrf2 binding activity to antioxidant-response elements (ARE).
AKBA (Acetyl-11-keto-β-boswellic acid) significantly inhibited human colon adenocarcinoma growth, showing arrest of the cell cycle in G1-phase and induction of apoptosis.
AKBA (Acetyl-11-keto-β-boswellic acid) triggered significant lipolysis in 3T3-L1 adipocytes as shown by reduced neutral lipids in cytosol and increased free fatty acids in culture medium. Increased lipolysis by AKBA was accompanied by up-regulation of lipolytic enzymes, adipocyte triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), and a decreased expression of lipid droplet stability regulator perilipin. In addition, AKBA (Acetyl-11-keto-β-boswellic acid) treatment reduced phenotypic markers of mature adipocyte aP2, adiponectin and glut-4 in mature adipocytes.
AKBA (Acetyl-11-keto-β-boswellic acid) significantly prevented the formation of intestinal adenomatous polyps without toxicity to mice. AKBA's activity both in the prevention of small intestinal and colonic polyps was more potently than aspirin. Histopathologic examination revealed that AKBA's effect, that is the reduction of polyp size and degree of dysplasia, was more prominent in larger sized polyps, especially those originating in colon.
AKBA (Acetyl-11-keto-β-boswellic acid) administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity. The activity of AKBA was more potent than that of aspirin.
AKBA (Acetyl-11-keto-β-boswellic acid) exhibited anti-cancer activity in vitro and in vivo. With oral application in mice, AKBA significantly inhibited SGC-7901 and MKN-45 xenografts without toxicity.